Global Peptide Synthesis Market Report 2024, with Revenue Data from 2020-2023, Forecasts and CAGRs Projections for 2024-2028 – ResearchAndMarkets.com




Global Peptide Synthesis Market Report 2024, with Revenue Data from 2020-2023, Forecasts and CAGRs Projections for 2024-2028 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Peptide Synthesis: Global Markets 2023-2028” report has been added to ResearchAndMarkets.com’s offering.

The global market for peptide synthesis is expected to grow from $90.1 billion in 2023 and projected to reach $157.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.8% during the forecast period of 2023 to 2028.

The report provides a detailed summary of the peptide synthesis market, with a focus on peptide therapeutics; a competitive landscape; and company profiles that include revenue, product portfolio and news in development. The report analyzes market trends and dynamics, including drivers, restraints and opportunities. This research study discusses historical year, base year and potential market size for the forecast period.

The report will enable key players, other strategists and start-ups to make informed decisions about the production, marketing and licensing of goods and services. Organizations, exporters and distributors should find the information about market development and trends useful. The segments of the market provided in the report are peptide type, applications and synthesis type. Regional market analysis is provided for all segments, and country-level analysis in some cases. Key developments and ESG information for the companies is provided based on the market.

The market is divided into segments and by application/industry as follows:

By peptide types:

• Synthetic peptides.
• Antimicrobial peptides.
• Hormonal peptides.
• Bioactive peptides.
• Collagen peptides.
• Others.

By application:

• Cancer.
• Diabetes.
• Neurology.
• Others (cardiology, rare diseases, etc.).
• Peptide therapeutics.
• Cosmetics.
• Nutraceuticals.
• Others (drug discovery, medical imaging).

By synthesis type:

• Solid-phase.
• Solution-phase.
• Hybrid-phase.

For each of these areas, current products in the market are identified, measuring the market size and identifying potential market drivers. Forecasts for 2028 are attained by analyzing the current competitors’ market shares for the base year of 2022.

By geographic region, the market is segmented into North America, Europe, Asia-Pacific and the Rest of World. The markets in countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico and GCC countries are analyzed. For market estimates, data is provided for 2022 as the base year, with estimates for 2023 and forecast values for 2028.

The Report Includes

• 63 data tables and 56 additional tables
• An overview of the global market for peptide synthesis
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Estimate of the actual market size and revenue forecast, and a corresponding market share analysis by product type, synthesis area, application, end-user, and region
• Facts and figures pertaining to major market dynamics, technological trends, latest developments in peptide production, pipeline drugs (manufactured using peptides), and future prospects
• Discussion of sustainability trends and factors, with emphasis on consumer attitudes, companies’ ESG scores, the future of ESG, case studies and the ESG practices of companies
• Overview of the major vendors along with an analysis of the industry structure, including company market shares, recent M&A activity and venture funding outlook
• Competitive intelligence on the leading market players, including their product developments, business strategies, key financials and segmental revenues
• Profiles of the leading global players, including Novo Nordisk A/S., AbbVie Inc., Lilly, Novartis Ag, AstraZeneca, and Teva Pharmaceutical

   

Key Attributes:

Key Topics Covered:

Chapter 1 Executive Summary

Chapter 2 Market Overview

• Peptide Therapeutics
• Importance of Peptides
• Peptide Synthesis
• Trends in Peptide Therapeutics

Chapter 3 Market Dynamics

• Market Drivers
  
  • Rising Incidence of Chronic Diseases
  • Developments in Peptide Drug Delivery
  • Increase in Biotech Spending
  • Increase in Infectious and Chronic Diseases
• Market Restraints
  • Issues in Sustainability in Synthetic Peptide Production
• Market Opportunities
  • Oral Peptide Therapeutics
  • Opportunities in Emerging Nations

Chapter 4 Emerging Technologies for Peptide Synthesis and Therapeutics Manufacturing

• Advances in SPPS in Aqueous Media
• Chemical Synthesis
• Peptide Drug Delivery
• Examples of New Developments, by Company
• Nissan Chemical Corp.
• Gyros Protein Technologies AB

Chapter 5 Market Analysis, by Segment

• Global Market for Peptide Synthesis, by Peptide Type
  • Synthetic Peptides
  • Antimicrobial Peptides
  • Hormonal Peptides
  • Bioactive Peptides
  • Collagen Peptides
  • Other Products
• Global Market for Peptide Synthesis, by Application
  • Peptide Therapeutics
  • Cosmetics
  • Nutraceuticals
  • Other Types of Applications
• Peptide Synthesis by Synthesis Type
  
  • Solid-phase
  • Solution-phase
  • Hybrid-phase
• Peptide Synthesis by Region
  
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 6 Competitive Landscape

• Top Players
• Strategic Analysis
• M&A Analysis
• M&A Deals in 2020-2023
• Flourishing Biotech Startups (2023)
  • Neumora Therapeutics Inc.
  • Altos Labs
  • Affini-T Therapeutics
  • Capstan Therapeutics
  • Septerna Inc.

Chapter 7 Sustainability in the Peptide Synthesis Industry: An ESG Perspective

• Importance of ESG among Peptide Therapeutics Manufacturers
• ESG Practices of Peptide Therapeutics Manufacturers

Company Profiles

• Abbott
• Abbvie Inc.
• Amgen Inc.
• Astrazeneca
• Boehringer Ingelheim International
• Bristol Myers Squibb Co.
• B. Braun Se
• Lilly
• Merck & Co. Inc.
• Moderna Inc.
• Novartis Ag
• Novo Nordisk A/S
• Sanofi
• Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/pph87e

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market




ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market

Tru Niagen^® expands to health-conscious Sprouts consumers in more than 400 locations across 23 states

LOS ANGELES–(BUSINESS WIRE)–$CDXC #ChromaDex—ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship product, Tru Niagen^®, the number one healthy-aging NAD+ supplement in the United States^†, is now available at Sprouts Farmers Market, marking its inaugural major grocery debut. As one of the fastest-growing retailers in the United States, Sprouts Farmers Market now offers Tru Niagen to its health-conscious consumers in more than 400 locations across 23 states.

“We are privileged to have Sprouts as the first major grocery chain to carry Tru Niagen,” said Rob Fried, CEO of ChromaDex and Founder of Tru Niagen. “This partnership advances our mission to broaden the access of Tru Niagen to a large, health-focused consumer base and aligns with our vision to help as many people as possible transform the way they age.”

The sole active ingredient in the clinically proven Tru Niagen supplement is NIAGEN^®, ChromaDex’s patented nicotinamide riboside (NR) ingredient, the most efficient and superior NAD+ precursor available. NAD+ is an essential coenzyme that plays a vital role in cellular processes including mitochondrial function, cellular energy production, and DNA repair. Embodying the highest scientific and quality standards, Tru Niagen is backed by two Nobel Prize winners, 30+ human clinical studies, 300+ published scientific studies, and has been accepted by the world’s most rigorous regulatory bodies.

Sprouts Farmers Market is known for its curated selection of healthy groceries and is a go-to destination for wellness enthusiasts and those embarking on their health and wellness journeys. Tru Niagen 300mg 30-count and Tru Niagen Immune bottles are now available in the women’s section of the dietary supplements aisle, providing Sprouts customers with easy access to the number one healthy-aging NAD+ supplement in the United States^†.

For more information about the science behind Tru Niagen, please visit www.truniagen.com. To find a Sprouts store near you, visit sprouts.com.

About ChromaDex:

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, NIAGEN^® (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

NIAGEN NR is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen^®, the number one healthy-aging NAD+ supplement in the United States^†. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com). ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information.

^†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

About Sprouts Farmers Market, Inc.:

True to its farm-stand heritage, Sprouts offers a unique grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspires wellness naturally with a carefully curated assortment of better-for-you products paired with purpose-driven people. The healthy grocer continues to bring the latest in wholesome, innovative products made with lifestyle-friendly ingredients such as organic, plant-based and gluten-free. Headquartered in Phoenix, and one of the largest and fastest-growing specialty retailers of fresh, natural and organic food in the United States, Sprouts employs approximately 31,000 team members and operates more than 400 stores in 23 states nationwide. To learn more about Sprouts, and the good it brings communities, visit about.sprouts.com.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to whether the partnership with Sprouts builds upon the Company’s mission to broaden access of Tru Niagen to a large health-focused consumer base. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could” or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Contacts

ChromaDex Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships

310-388-6706 ext. 689

kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:
Ben Shamsian

Lytham Partners

646-829-9701

shamsian@lythampartners.com

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024




Ligand to Report First Quarter 2024 Financial Results on May 7, 2024

JUPITER, Fla.–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.

Conference Call and Webcast Information

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.

We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.

Contacts

Investors:
Michael Jeong

investors@ligand.com
(561) 214-4232

LifeSci Advisors

Bob Yedid

bob@lifesciadvisors.com
(516) 428-8577

Media:

Kellie Walsh

media@ligand.com
(914) 315-6072

Agenus to Provide First Quarter 2024 Financial Report and Corporate Update




Agenus to Provide First Quarter 2024 Financial Report and Corporate Update

LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

Conference Call:

To access dial-in numbers, please register here.

Conference ID: 73242

A live webcast and replay of the conference call will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/928123199.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding a its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words “may,” “believes,” “expects,” “anticipates,” “hopes,” “intends,” “plans,” “forecasts,” “estimates,” “will,” “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2022, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contacts

Investors
917-362-1370

investor@agenusbio.com

Media
917-362-1370

communications@agenusbio.com

Sapio Sciences Launches New Multimodal Registration Capabilities For Its Lab Informatics Platform




Sapio Sciences Launches New Multimodal Registration Capabilities For Its Lab Informatics Platform

Sapio Sciences has enhanced its lab informatics platform with new multimodal entity registration capabilities for diverse product types, including small and large molecules and conjugates

BALTIMORE–(BUSINESS WIRE)–Sapio Sciences, the science-aware™ lab informatics platform, today announced the launch of its new multimodal registration capabilities. This new functionality unifies small-molecule, large-molecule, and multimodal discovery workflows, including entity registration, on a single platform. With these latest features, Sapio is helping R&D teams overcome the collaboration and efficiency challenges traditionally associated with the development of multimodal therapies and products.

New modalities, such as recombinant proteins, peptides and engineered antibodies are key drivers of biopharmaceutical industry growth. According to BCG, over the past few years, revenues from new-modality products increased by $60 billion, while revenues from conventional products declined by $10 billion. Furthermore, BCG projects that the percentage value of new modalities in the five-year forward pipeline between 2019 and 2023 will increase from 41% to 56%, far outpacing conventional ones.

“The days of viewing drug discovery through the separate lenses of small molecules and large molecules are outdated,” said Kevin Cramer, president and CEO of Sapio Sciences. “Today, drug discovery in biopharma is increasingly multimodal, and leading-edge laboratories require a single unified informatics platform that supports small-molecule, large-molecule, and new modality discovery workflows, including registration.”

Today, companies typically use separate registration systems, one for small molecules and another for large molecules. For multimodal discovery, separate registration becomes problematic. A unified registration system solves this by enabling researchers from diverse departments such as chemistry and molecular biology to work together on new modalities seamlessly, manage all data in one place, have one system for regulatory compliance, and collaborate with a single source of truth.

The foundation of the Sapio Platform is a single materials management system that does not distinguish between small-molecule, large-molecule, or multimodal entities — rather, they are all collected and managed as molecular materials with attributes that record the unique characteristics of each type of entity. Uniquely, Sapio also connects its sample management with registered entities for seamless data visualizations and traceability. As a result, chemists and biologists can work together on a single, unified drug discovery platform that combines Sapio LIMS™, Sapio ELN™ and Sapio Jarvis™ to integrate and harmonize collective scientific data across the laboratory informatics enterprise.

New biotech ventures will want to adopt the Sapio Platform now to address leading-edge new modality drug discovery opportunities and position themselves for accelerated discovery and insights from day one. Established biopharma enterprises will want to reassess the limitations and risks of currently deployed separate chemistry- and biology-centric informatics and evaluate the benefits and advantages of a single unified lab informatics platform from Sapio to optimize leading-edge multimodal drug discovery.

About Sapio Sciences

Sapio Sciences’ mission is to improve lives by accelerating discovery, and because science is complex, Sapio makes technology simple. Sapio is a global business offering an all-in-one science-aware™ lab informatics platform combining cloud-based LIMS, ELN, and Jarvis data solutions.

Sapio serves some of the largest global and specialist brands, including biopharma, CRO/CDMOs and clinical diagnostic labs across NGS genomic sequencing, bioanalysis, bioprocessing, chemistry, stability, histopathology, and in vivo studies.

Customers love Sapio’s platform because it is robust, scalable, and with no-code configuration, can quickly adapt to meet unique needs. For more information, visit www.sapiosciences.com and follow us on LinkedIn.

Contacts

Rick Halton

Vice President, Global Marketing

+1 (410) 800-4620

marketing@sapiosciences.com

ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management




ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management

ZYUS Receives Patent from United States Patent and Trademark Office (“USPTO”) Supporting ZYUS’ Lead Drug Candidate

SASKATOON, Saskatchewan–(BUSINESS WIRE)–#HealthcareInnovation–ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, announced today that the USPTO issued U.S. Patent No. 11,963,943, entitled FORMULATION FOR PAIN MANAGEMENT on today’s date. The patent, held by ZYUS’ wholly owned subsidiary, ZYUS Life Sciences Inc., is based on International Patent Application No. PCT/CA2020/050588 with claims pertaining to ZYUS’ lead drug candidate, Trichomylin^® softgel capsules. This marks the seventh issuance of a patent in this patent family, joining other jurisdictions such as Canada, Australia, Israel, India, Korea and South Africa. The issuance of this patent by the USPTO underscores ZYUS’ commitment to innovation and dedication to improving patient outcomes through the development of non-opioid-based pharmaceutical solutions as a viable alternative for managing pain.

Intellectual Property Portfolio

ZYUS’ intellectual property portfolio contains multiple patent families related to fixed-dose cannabinoid-based formulations for the treatment of pain and a variety of other clinically unmet needs. Including the U.S. patent issued covering its lead drug candidate, Trichomylin^® softgel capsules, ZYUS’ intellectual property portfolio, with a focus on novel therapies, currently contains seven issued patents, eleven nonprovisional patent applications that have been filed internationally, four continuation-in-part applications filed in the U.S. and one provisional patent application directed to formulations and treatments.

Trichomylin^® Softgel Capsules Phase 2 Clinical Trial

Trichomylin^® softgel capsules have been formulated with a proprietary fixed-dose combination, specifically designed for the management of chronic pain by delivering a balanced ratio of three cannabinoids – cannabichromene (“CBC”), cannabidiol (“CBD”) and delta-9-tetrahydrocannabinol (“THC”). ZYUS’ previously announced Phase 2 Clinical Trial will assess the preliminary efficacy, safety and tolerability of Trichomylin^® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.

“Receiving this patent for the treatment of pain using our non-opioid-based formulation validates our ongoing commitment to innovation and investment in research, marking a pivotal step towards the development of this urgently needed medicine. To our knowledge, this is the first time a U.S. patent has been awarded for a cannabinoid-based fixed-dosed formulation containing CBC, CBD and THC,” said Brent Zettl, President and CEO of ZYUS. “Our clinical development program for the Trichomylin^® formulation is well-positioned for success given both the new patent issuance and recently announced Phase 2 Clinical Trial, which aims to demonstrate preliminary efficacy, safety and tolerability of this novel drug candidate. We intend to use the data from our extensive pre-clinical and non-clinical studies, completed Phase 1 Clinical Trial and proposed Phase 2 Clinical Trial to form the basis of an Investigational New Drug application with the U.S. FDA.”

About ZYUS Life Sciences Corporation

ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS’ unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients’ lives. For additional information, visit www.zyus.com or follow us on X (formerly known as Twitter) @ZYUSCorp.

Cautionary Note Regarding Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the Company’s business, the Company’s ability to advance clinical research activities, realize on its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates such as Trichomylin^® softgel capsules, introduce products that act as alternatives to current pain management therapies such as opioids, advance Phase 2 clinical development of Trichomylin^® softgel capsules and Investigational New Drug applications with the US. FDA. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans”, “will” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company’s business, the Company’s ability to advance clinical research activities, realize on its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates such as Trichomylin^® softgel capsules, introduce products that act as alternatives to current pain management therapies such as opioids, advance Phase 2 clinical development of Trichomylin^® softgel capsules and file Investigational New Drug applications with the US. FDA are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the Company will be able to advance its clinical research activities and further operations, realize its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates, introduce products that act as alternatives to current pain management therapies such as opioids, advance Phase 2 clinical development of Trichomylin^® softgel capsules or file Investigational New Drug applications with the US. FDA. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Contacts

ZYUS Media Inquiries

media@zyus.com
1-833-651-7723

ZYUS Investor Relations

investors@zyus.com

Orthofix Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024




Orthofix Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024

LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its first quarter 2024 financial results on Tuesday, May 7, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 a.m. ET the same day.

Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations, and entering the event passcode 9556380. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com.

About Orthofix

Orthofix is a leading global spine and orthopedics company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and a leading surgical navigation system. Its products are distributed in more than 60 countries worldwide.

The Company is headquartered in Lewisville, Texas, where it conducts general business, product development, medical education and manufacturing, and has primary offices in Carlsbad, CA, with a focus on spine and biologics product innovation and surgeon education, and Verona, Italy, with an emphasis on product innovation, production, and medical education for orthopedics. The combined Company’s global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Wayne, PA, Olive Branch, MS, Maidenhead, UK, Munich, Germany, Paris, France and São Paulo, Brazil.

Contacts

Investor Relations
Louisa Smith, Gilmartin Group

ir@orthofix.com

Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform




Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform

— Company raised $25 million in seed financing led by Forbion and Wellington Partners —

— Seamless to develop programmable recombinases focused on precise, large edits targeting diseases of significant unmet medical need —

DRESDEN, Germany & LEXINGTON, Mass.–(BUSINESS WIRE)–Seamless Therapeutics today announced the appointments of Albert Seymour, Ph.D., as its new President and Chief Executive Officer and Adam Rosenberg as Independent Chairman of the company’s Board of Directors. Both bring longstanding track records of successfully leading trailblazing biotechnology companies with an emphasis on gene editing and novel technologies. In addition, their combined experience will be instrumental in establishing Seamless Therapeutics’ Research and Development (R&D) activities in the US. In conjunction with the leadership additions, Seamless Tx Inc. will be established in Lexington, MA to focus on the translation of the differentiated recombinase technology from early discovery into the clinic. Dr. Seymour will be based in this office and replace Acting CEO and Co-Founder, Dr. Anne-K. Heninger, who will remain at the company and continue to oversee operations at the Dresden site as Head of Operations.

Seamless is translating major breakthroughs in programming recombinases, a class of enzymes that have been widely used in scientific research for decades, to transform their accuracy and flexibility enabling therapeutic gene editing. The company’s unique technology platform allows for site specific programmable recombinases that are engineered for specificity and activity to precisely excise, exchange, invert or insert DNA fragments in any target gene sequence. Early in vivo preclinical evidence has shown that Seamless’ programmable recombinases can precisely edit a 138 kilobase fragment through inversion. Editing through this process is independent of the cell’s DNA repair pathway. This platform provides opportunities to address multiple disease-causing mutations with a single therapeutic as well as expand gene editing to non-dividing cell types.

The company has raised $25 million in seed financing to date led by Forbion and Wellington Partners to advance its proprietary technology. The team is currently focused on generating a pipeline of innovative product candidates that aim to treat human disease irrespective of the specific genetic alteration.

“Seamless Therapeutics is at the forefront of the next wave of innovation in gene editing with its unique platform and comprehensive toolbox capable of programming recombinases. The platform technology coupled with the growth of our R&D team in Lexington provides the tools and expertise to precisely correct a range of DNA mutations at specific sites in the genome. Our goal is to continue to innovate and bring novel therapeutics forward for a range of disorders thereby addressing significant unmet medical needs,” said Albert Seymour, Ph.D., Chief Executive Officer of Seamless Therapeutics. “The potential of Seamless Therapeutics’ technology and its future growth is very exciting, and I look forward to working with Adam in his new role as Chairman of the Board of Directors, and our international team to bring a differentiated pipeline of gene editing candidates to the clinic.”

“The field of gene editing is witnessing a new era. Relative to current editing approaches, which have provided a critical step forward in the development of novel therapeutics for patients in areas of high unmet need, Seamless Therapeutics has a first-mover position with its recombinase-focused technology. Programmable recombinases have the potential to precisely repair genetic alterations that cause disease using large or small edits as required,” added Adam Rosenberg, Independent Chairman of the Board of Seamless Therapeutics. “Together with Albert, the Seamless team and the Board, we are in a great position to deliver the technology’s inherent potential to create a new class of potentially curative treatments for patients globally.”

Dr. Seymour has over 25 years of combined experience in the field of human genetics and pharmaceutical R&D and is responsible for advancing the development of multiple therapeutic programs. Prior to his role at Seamless Therapeutics, he served as Chief Scientific Officer and later President and Chief Executive Officer of Homology Medicines, a clinical-stage genetic medicines company developing treatments for rare diseases. Before joining Homology Medicines, he served in several senior leadership positions at Shire and Pfizer. Dr. Seymour is currently on the Board of Directors at Ensoma and Iris Medicines. He holds a Ph.D. in Human Genetics from the University of Pittsburgh in the U.S.

Mr. Rosenberg has over 20 years of experience in building and leading innovative life sciences companies, most recently as founding CEO of Aliada Therapeutics, Athenen Therapeutics (merged with Eliem Therapeutics: ELYM) and Sionna Therapeutics. Previously, he was President, CEO, and member of the Board of Directors of Rodin Therapeutics until its acquisition in 2019. He also served as CEO and Co-Founder of Link Medicine and Teleos Therapeutics. Adam is currently Chair of Ambagon Therapeutics, and serves as Director on the boards of other venture-backed and public companies.

About Seamless Therapeutics

Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach that has the potential to address unmet medical needs in patients with severe conditions. Our technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. We are applying our proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.

Contacts

Seamless Therapeutics
Albert Seymour, CEO

Email: info@seamlesstx.com

Seamless Therapeutics media inquiries
Trophic Communications

Stephanie May and Jacob Verghese

Tel: +49 171 1855682 or +49 151 7441 6179

Email: seamless@trophic.eu

Encoded Therapeutics Provides Pipeline Updates From Its Vector Engineering Platform Ahead of Four Preclinical Presentations at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)




Encoded Therapeutics Provides Pipeline Updates From Its Vector Engineering Platform Ahead of Four Preclinical Presentations at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

• Four newly disclosed programs follow clinical-stage Dravet syndrome gene therapy ETX101
• Non-human primate (NHP) data support non-monogenic program in Lennox-Gastaut syndrome and demonstrate proof-of-concept for vectorized miRNA-based UBE3A upregulation in Angelman syndrome
• Promising early data suggest potential next generation therapeutics for neuropathic pain & Alzheimer’s disease

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Encoded Therapeutics Inc., a biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, today unveiled multiple pipeline programs ahead of the 27^th ASGCT Annual meeting on May 7 – 11, 2024 in Baltimore, MD. Presentations will highlight progress of preclinical programs for Angelman syndrome, Lennox-Gastaut syndrome (LGS), STXBP1-related disorders (STXBP1-RD), Alzheimer’s disease (MAPT) and neuropathic pain (SCN9A), together with innovations in the company’s vector engineering platform.

“Our ASGCT presentations showcase the depth and versatility of our vector engineering platform to develop highly specific precision therapies for CNS disorders with high unmet need,” said Stephanie Tagliatela, Chief Scientific Officer at Encoded. “Combining our novel regulatory elements and transgenes provides control of expression in target cells, potentially enabling treatment of devastating, intractable diseases. Building on our strong foundation in neuroscience, we are leveraging the experience and infrastructure established for our Dravet syndrome program, ETX101, to rapidly advance our promising pipeline of potentially best-in-class gene therapies.”

Platform Innovations

Encoded is engineering precision and selectivity into gene therapy constructs by combining highly selective and potent regulatory elements (REs) with novel transgenes to customize expression and functionality while minimizing off-target effects. These modular elements are compatible with multiple capsids and gene delivery systems.

Novel REs developed by Encoded include those for GABA selectivity to target expression to GABAergic (inhibitory) interneurons, utilized by the clinical-stage program ETX101 for Dravet syndrome and the preclinical program for LGS. For STXBP1-RD, regulatory element engineering has been harnessed to drive potent, neuron-specific expression in the brain, while de-targeting expression in dorsal root ganglia (DRG).

Engineered transgenes include transcription factors (eTFs) that upregulate the expression of endogenous genes as well miRNA sequences derived from Encoded’s miRNA discovery platform. A miRNA approach is utilized by the Angelman syndrome, Alzheimer’s disease and neuropathic pain programs, each of which demonstrate robust gene silencing or knockdown of their respective targets.

“The data we’re sharing at ASGCT highlights our platform’s ability to achieve precise, targeted expression of transgenes with unique functionality, addressing technical limitations that exist today. This enables us to potentially unlock first-in-class gene therapies in monogenic disorders, like Dravet and Angelman syndromes, while also advancing potentially best-in-class gene therapies into more common diseases such as LGS, Alzheimer’s disease and neuropathic pain,” said Encoded CEO Kartik Ramamoorthi, Ph.D. “This is a significant maturation of our pipeline, and future success in these indications has the potential to transform the lives of many people living with severe CNS diseases.”

ASGCT Annual Meeting Presentations

Oral Presentation Details

Title: GABA Selective AAV-mediated Gene Therapy Provides Durable Seizure Protection in Multiple Refractory Epilepsy Models (Abstract #19)

Session: AAV Vectors – Preclinical and Proof-of-Concept: Therapy Focus

Date & Time: Tuesday, May 7, 1:45–2:00 p.m. ET

Location: Ballroom 2

Poster Presentation Details

Title: Advancing Gene Therapy for STXBP1-related Disorders Through Targeted Vector Engineering: Efficacy and Safety Results in Mice and Non-Human Primates (Abstract #508)

Date & Time: Wednesday, May 8, 5:30–7:00 p.m. ET

Location: Exhibit Hall

Title: A Vectorized miRNA-based Approach to Unsilence UBE3A in Angelman Syndrome (Abstract #1125)

Date & Time: Thursday, May 9, 5:30–7:00 p.m. ET

Location: Exhibit Hall

Title: Identification of Potent and Selective AAV-miRNA Candidates to Knockdown Non-Monogenic Neurological Targets SCN9A (Pain) and MAPT (Tauopathies) (Abstract #1601)

Date & Time: Friday, May 10, 5:30–7:00 p.m. ET

Location: Exhibit Hall

Scientific Symposium Details

Title: Searching for Goldilocks – Scaling for AAV Clinical Dose Prediction

Presentation: Dose Scaling from Preclinical Models to First-In-Human (FIH) for Local CNS AAV Gene Therapies

Date & Time: Thursday, May 9, 8:00–8:25 a.m. ET

Location: Ballroom 4

Presenter: Stephanie Tagliatela

Full abstracts are available on the ASGCT meeting website.

About Encoded Therapeutics

Encoded Therapeutics is a clinical-stage genetic medicines company developing potentially disease-modifying therapies to improve the lives of people with severe CNS disorders. Our proprietary vector engineering approach combines novel regulatory elements and payloads with AAV vectors to unlock innovative solutions for debilitating, intractable CNS conditions. At the forefront is our flagship clinical program, ETX101 for Dravet syndrome, which targets the underlying cause of the disorder to enable highly selective upregulation of SCN1A for potentially long-lasting benefit. In parallel, we are advancing a pipeline of potentially best-in-class programs to address significant unmet needs across both monogenic and prevalent CNS conditions. Harnessing our proprietary technology platform and expertise, we are able to efficiently advance programs from discovery through clinical development. Encoded is committed to pioneering breakthrough treatments for CNS disorders. For more information, please visit www.encoded.com.

Contacts

Jennifer Gorzelany

communications@encoded.com
650-515-9695

Vizient conducts first Insight: Cell, Gene, and Specialty Pharmacy Symposium




Vizient conducts first Insight: Cell, Gene, and Specialty Pharmacy Symposium

IRVING, Texas–(BUSINESS WIRE)–Vizient, Inc. hosted its inaugural Insight: Cell, Gene, and Specialty Pharmacy Symposium, bringing together leading healthcare providers, payers and manufacturers of high-cost, ultra-specialty pharmaceuticals along with other stakeholders to discuss the promise and unique challenges of the rapidly expanding market of cell, gene and other advanced therapies. The three-day meeting began April 8 in Atlanta.

To date, there are 22 ultra-specialty treatments approved in the U.S. with prices ranging from $450,000 to $4.25 million for a single dose treatment. Some estimates predict the market for these agents could reach $25 billion by 2026.

“These innovations and their transformative potential offer tremendous hope not only for the rare diseases to which they are targeted today, but for broader patient populations as the innovations continue to expand,” said keynote speaker Madeleine McDowell, MD, senior principal at Vizient. “These advancements may ultimately allow us to innovate ourselves out of some of the current public health crises that have been so enduring and so problematic.”

The meeting consisted of presentations and panel discussions focused on operational and financial challenges that providers, suppliers and payers must navigate to enable access to these agents, including:

• Implementing best practices for managing financial impact and payer coverage decisions
• Managing unique storage and logistical needs
• Addressing the requirements and authorization processes to become a qualified treatment center
• Establishing multidisciplinary teams across health systems that include all operational aspects of delivering cell and gene therapy such as finance, pharmacy, manage care teams, laboratory, nursing, and physicians.
• Ensuring equitable access for all patients

“Our traditional supply chain, patient care and coverage models have failed to keep pace with the clinical advancement of these medications,” said Steven Lucio, PharmD, senior principal at Vizient. “That has to change if providers and their patients are to realize the full benefit of the enormous investments being made in these areas of disease management.”

Through symposiums like these and our advanced therapy solutions, Vizient is working to promote rapid innovation in the supply chain, patient management and coverage processes that accompany these increasingly influential categories of drugs. View a summary of the Insight: Cell, Gene, and Specialty Symposium. For more information on cell and gene therapy, please see the Vizient 2024 Winter edition of the Pharmacy Market Outlook. For more information on Vizient’s advanced therapy solutions, please contact pharmacyquestions@vizientinc.com.

About Vizient, Inc.

Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company, serves more than 65% of the nation’s acute care providers, which includes 97% of the nation’s academic medical centers, and more than 35% of the non-acute care market. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents $140 billion in annual purchasing volume. Vizient’s solutions and services improve the delivery of high-value care by aligning cost, quality and market performance. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.

Contacts

Donna Ledbetter

(972) 830-6321

donna.ledbetter@vizientinc.com